Cutaneous, acral and mucosal subtypes of melanoma were evaluated by wholegenome sequencing. The heavily mutated landscape of coding and non-coding mutations in cutaneous melanoma resolved novel signatures of ultraviolet radiation mutagenesis. However, acral and mucosal melanomas were dominated by structural changes and mutation signatures of unknown aetiology, not previously identified in melanoma. The number of genes affected by recurrent mutations disrupting noncoding sequences was similar to that affected by recurrent mutations to coding sequences. Significantly mutated genes included BRAF, CDKN2A, NRAS and TP53 in cutaneous melanoma, BRAF, NRAS and NF1 in acral melanoma and SF3B1 in mucosal melanoma. Mutations affecting the TERT promoter were the most frequent of all, however, neither they nor ATRX mutations, which correlate with alternative telomere lengthening, were associated with greater telomere length. Most melanomas had potentially actionable mutations, the majority in components of the mitogenactivated protein kinase and phosphoinositol kinase pathways.
aberrations in acral and mucosal melanomas. These latter subtypes fundamentally differ in pathogenesis and therapeutic targets from cutaneous melanoma.
Study sample and mutation burden
The 183 melanoma samples comprised 75 primary tumours, 93 metastases and 15 cell lines derived from metastases; 35 were acral melanomas (arising from palms, soles or nail beds of the hands or feet), eight were mucosal and the remainder cutaneous (Supplementary Table 1 ). WGS identified 20,894,255 substitutions (range 1,610 to 777,275 per tumour) and 96,467 small insertions/deletions (indels) (range 0 to 10,114 per tumour) at an average rate of 38.23 mutations per megabase (Mb) (range 0.54 to 260 mutations/Mb) (Supplementary Table 1 and Fig. 1 ), the 156,770 coding mutations (range 19 to 5,536 per tumour) comprising 0.8% (Supplementary Table 2 ). Single nucleotide variant (SNV) and indel frequencies varied by melanoma subtype (t-test, P <1 X 10 -7 ), with >18 times more of these mutations in cutaneous (mean 49.17 mutations/Mb, range 0.71 to 259.69 mutations/Mb) than in acral and mucosal melanomas (mean 2.64 mutations/Mb, range 0.54 to 15.25 mutations/Mb) ( Fig. 1b ). Somatic structural variants (SV) were more frequent in acral and mucosal (mean 342.40, range 6 to 1,148) than in cutaneous melanomas (mean 101, range 3 to 1,123) (t-test, P <1 X 10 -6 ) ( Fig. 1c,d ). Greater proportions of the acral and mucosal melanoma genomes showed copy number variation (CNV), as in previous exome sequencing 3 ; more regions were amplified (Mann-Whitney test, P < 1.46 X 10 -4 ) and more genomes were aneuploid (chi-square test, P = 0.049) than in cutaneous melanomas (Extended Data 1).
UVR and non-UVR mutation spectra
An algorithm using the sequence context of each mutation 1 identified 12 signatures, which varied considerably by melanoma subtype (Fig. 2a-c ). Most melanomas (total n = 139; 136 cutaneous) were dominated by three novel signatures of UVR exposure (signatures 7a, 7b, and 7c), recapitulating UVR signature 7 previously identified by exome sequencing 1 (Extended Data 2). The predominantly C>T substitutions at TpC dinucleotides (mutated base underlined) of signature 7a are likely due to repair of 6,4-photoproducts 8 . Signature 7b involves C>T substitutions at CpC and CpC, characteristic of cyclobutane pyrimidine dimers 8 . Signature 7c has high levels of T>C and T>A mutations, potentially due to indirect DNA damage after UVR. Forty-four tumours, comprising 40 acral or mucosal melanomas and four cutaneous, all from infrequently sun-exposed sites, showed striking differences from the UVR-dominant group (Fig. 2 ). Six of nine signatures observed in this group have been described in other cancers 9 but never previously in melanoma and are presumably unrelated to UVR exposure. The most frequent were signature 1, the result of endogenous spontaneous deamination of 5-methylcytosine, and signature 5, ubiquitous in cancers of many types and of unknown aetiology 10 (Extended Data 2). Signature 13, attributed to activity of AID/APOBEC cytidine deaminases, occurred in 52 samples (28%) and all melanoma subtypes. Signatures 8, 17 and 18, of unknown aetiology, occurred in all melanoma subtypes at a combined frequency of 7-28%. Signature 6, associated with defective mismatch repair, was seen in the single cutaneous melanoma with a high MSIsensor 11 score.
Structural variants, telomere length
The combined frequency of all SV (deletions, duplications, tandem duplications, and foldback inversions), was higher in acral and mucosal melanomas than in cutaneous melanomas (t-test, P < 1 X 10 -6 ) ( Fig. 1c and Supplementary Table 3 ). Acral and mucosal melanomas exhibited substantially more clusters of breakpoints, indicating more frequent complex rearrangements such as breakage-fusion-bridge and chromothripsis (Extended Data 3a). We detected complex rearrangements including breakage-fusion-bridge-like in 18% (n = 32) of tumours, most of which (n = 20, 63%) were acral or mucosal melanomas (Extended Data 4, 5) .
WGS provided the first opportunity to assess effects of mutagenic processes and driver mutation profiles of melanoma on immortalisation via telomere length 12, 13 (Methods and Extended Data 6b). Telomere length varied widely among the 183 samples, ranging from 6fold shorter to 10-fold longer than the matched normal for each patient (Extended Data 6a).
Telomere length was not correlated with melanoma subtype (Extended Data 6c), chromothripsis, or breakage-fusion-bridge events (Extended Data 3).
Non-coding mutations
All mutations were annotated for genomic context including regulatory, untranslated and protein coding regions, the first such comprehensive survey in melanoma and one of the first in any cancer. TERT promoter mutations 14, 15 were most common (Sanger sequencing), with 115/167 (69%) overall and 86% of cutaneous melanomas mutated at one or more of four positions upstream of the initiation codon (Extended Data 6d). These mutations created new binding sites for the ETS family transcription factor GABP 16 , and were mutually exclusive with the exception of two samples with extremely high mutation burdens. In keeping with previous findings for acral melanoma 17 , these mutations were less prevalent in acral and mucosal melanomas (4/38: 11%), accounting for their association with lower SV and higher SNV burden (Fisher's exact test, P < 1 X 10 -17 ). There was no association between TERT promoter and BRAF mutation (chi-square test, P > 0.09), in contrast to previous reports 18 .
These putatively activating TERT promoter mutations were associated with modestly reduced telomere length (Mann-Whitney, P = 0.0022) (Extended Data 6e-g). Telomere elongation in cancer depends either on TERT or a process of alternative lengthening of telomeres (ALT) 19 , often driven by mutations in ATRX 20 . The latter occur mutually exclusively with TERT promoter mutations in glioblastoma 21 . Ten melanomas (all cutaneous) had predicted loss-of-function mutations in ATRX, including two nonsense mutations, but paradoxically nine of these tumours also carried mutations in the TERT promoter and there was no association between ATRX mutation and telomere length (data not shown).
Therefore, mutational activation of TERT does not simply facilitate telomere length extension, and the relationships between alternative telomere maintenance mechanisms, telomere length and immortalisation in melanoma must be complex.
All genes with recurrent mutations in the promoter, 5'-UTR or 3'-UTR are listed (Supplementary Tables 4-6 ). To detect non-coding elements with an accumulation of functional mutations we used OncodriveFML 22 , which detects signals of positive selection in mutations of coding and non-coding elements. Because of the high mutation rate at active transcription factor binding sites (TFBS) in melanoma 22 , we used a version of OncodriveFML (version 1.1) that permutes mutations locally to assess if the mutations observed disrupt or create TFBS more often than expected by chance. Promoter regions of nine genes were significantly (q-value < 0.25) biased towards high impact mutations: creating new TFBS in BLCAP, KBTBD8, TERT and ZNF778, disrupting them in NSUN6 and RNF185, and with other impacts in RALY, RPL29 and RPS27 (Supplementary Table 4 ). Only in the case of TERT (as previously reported 15 ), RNF185 and RPS27 was an effect of these mutations on gene expression supported. In a further six genes with five or fewer occurrences of a promoter mutation (NUDT10, PNPLA2, CCP110, UAP1, UBAC2 and ZWINT) OncodriveFML predicted creation of novel TFBS, however too few tumours had such mutations for expression comparisons with wild type tumours to be informative.
Recurrent mutations in the promoter of NFKBIE were present in 10/183 (5%) tumours including 3/9 desmoplastic melanomas 23 . The commonest (chr6: 44233400) occurred in five melanomas, all cutaneous but lacking a desmoplastic component (Extended Data 7b).
Mutations at this and one other position (chr6: 44233417) have been reported previously, but the other four sites are novel (Extended Data 7b) and presumably lie outside the captured exome in the previous study. NFKBIE promoter mutations are thus enriched in desmoplastic melanomas (Fisher's exact test, P < 0.0084), but are also potential drivers of other cutaneous melanomas.
The most frequent 5'-UTR hotspot mutation, detected in 19/183 samples, was at the transcription start site of RPS27 (chr1: 153963239 C>T) 2,24 and a dinucleotide mutation was detected in one patient (chr1: 153963239-153963240 CT>TC). RPS27 also had several recurrent promoter mutations (Extended Data 7c), none predicted to cause gain or loss of TFBS. Recurrent mutations also occurred in the 5'-UTR of PES1 (Extended Data 7d), RPS14, CHCHD2 and MRPS31 ( Supplementary Table 5 ), the latter identified as a common hotspot coding mutation by TCGA 2 . The 5'-UTR regions of ERGIC3, PSMD8 and TGS1 were significantly biased towards high functional impacting mutations and were expressed in most tumours, however none showed expression differences associated with mutation status so their significance as drivers remains uncertain. TCGA did not report 3'-UTR mutations; we observed recurrent (n≥5) 3'-UTR mutations in 18 genes ( Supplementary Table 6 ). Only 11 of these genes were expressed in the tumour cohort and none has been associated with melanoma, except PTPRT which was recently reported to have frequent coding mutations 25 .
Key coding mutations and TCGA genomic subgroups
Two tools were used to identify significantly mutated genes (SMG) in each of the three melanoma subtypes (MutSigCV and OncodriveFML, q<0.1; Supplementary Table 7 ). Four cutaneous melanoma SMG were supported by both methods (BRAF, CDKN2A, NRAS and TP53), and five (ARID2, CWH43, NF1, PTEN and RB1) were supported by one method.
SF3B1 was identified as a SMG, for the first time in mucosal melanoma, by OncodriveFML.
In acral melanoma, OncodriveFML identified BRAF, KIT, MAP2K2, NF1 and NRAS as SMG.
Mutation frequencies of previously reported melanoma driver genes 2,3,25-29 , varied considerably between melanoma subtypes. For example, no acral or mucosal melanomas had mutations in TP53, PTEN, DDX3X, RASA2, PPP6C, RAC1 or RB1, indicating that the molecular pathways driving these melanoma subtypes differ markedly from those driving cutaneous melanoma. In line with previous studies 30 , KIT mutations occurred more frequently in acral (3/35) and mucosal melanomas (2/8) than in cutaneous melanomas (6/140) (chi-square test, P < 0.044). The distribution of mutations in selected melanoma genes ( Supplementary Table 8 ) is shown in Fig. 3 . SV and CNV contributed heavily to the overall mutation frequency of some melanoma driver genes, especially NF1, TP53, PTEN and KIT (Extended Data 1b,c; Fig. 3 ). BRAF hotspot mutations were usually amplified, and these SV tended to involve MET, adjacent on chromosome 7. Similarly, KIT and PDGFRA, co-located within 0.35 Mb on chromosome 4, were frequently co-amplified. MITF amplifications were present in 10% of samples, and in all three melanoma subtypes. Many acral and mucosal melanomas had SV and high-level amplifications on the long arm of chromosome 11, often targeting CCND1 (Extended Data 3c).
We analysed the genomic subgroups of melanoma proposed by TCGA: BRAF mutated, RAS mutated, NF1 mutated or triple wild-type (Extended Data 8 and 9, Fig. 3a ) 2 . NF1 aberrations occurred in 32/183 (17%) samples, and in 14 they were bi-allelic; 23 had point mutations/small indels only (15 nonsense, four missense, three splice site and one frameshift). SV contributed heavily ( Fig. 3b ) to mutation burden in NF1, so previous studies in which SV were not assessed will have underestimated the NF1-mutated group and overestimated the proportion of triple wild-type melanomas. NF1 mutation was found to cooccur with RASA2 mutation (Fisher's exact test, P < 0.003), as recently described 28, 31 .
Most mucosal and acral (n = 22/43, 51%) melanomas, but only 15/140 (11%) cutaneous melanomas lacked BRAF, NRAS or NF1 mutations; mutations in other cancer driver genes were frequent in this triple wild-type group. The latter included loss-of-function mutations in CDKN2A, TP53 and ARID2, and activating hotspot mutations in GNAQ and SF3B1. Notably, one GNAQ and three SF3B1 mutations, commonly mutated in uveal 32, 33 but not cutaneous melanoma 2 , were found exclusively in four of six triple wild-type mucosal melanomas, marking an unappreciated set of driver genes and pathways shared by mucosal and uveal melanomas. Seven triple wild-type melanomas carried mutations in KIT, five of which had high-level amplifications. Triple wild-type melanomas had more focal amplifications of KIT, CCND1, MDM2 and KRAS than did non-triple wild-type melanomas (Fisher's exact test, P < 5.4 X 10 -5 , 1.8 X 10 -5 , 0.018, 0.003, respectively).
Gene fusions
Gene fusions targeted several genes previously associated with melanoma (RAF1 34 , RAC1 3 , 29 , TRRAP 37 and PLCB4 37 ) (Supplementary Table 3 ) and known melanoma tumour suppressor genes: NF1 (n = 3), PARK2 (n = 2), TP53, PTEN, and PPP6C. RAF1 gene fusions, shown to increase MEK phosphorylation compared to wild-type RAF1, were observed in one triple wild-type and one NF1-mutated tumour 38 . The same RAF1 exons were retained in both fusions, albeit fused to different genes (CDH3 and GOLGA4) (Extended Data 9). In RNAseq of 44 samples 17 of 136 potential fusion genes were expressed (Supplementary Table 3 ). Table 3 ), the most frequently affected being PAK1 (n = 5 samples: four acral melanomas, two of which were triple wild-type, and one cutaneous carrying a BRAF V600E mutation). These PAK1 fusions are unlikely to be activating: the kinase domain was retained in four of five samples, in each case there was a different gene fusion partner (AQP11, FCHSD2, TENM4, OR9Q1) and two to four additional breakpoints within the PAK1 gene. The next most frequently fused kinase gene was DGKB, with two fusions in acral triple wild-type melanomas and one in a cutaneous BRAF V600E mutated sample, each with multiple breakpoints within the DGKB gene with likely loss of function.
Fusions involved several kinase genes (Supplementary

Signalling activation and clinical implications
All subtypes were dominated by mutations to the MAPK, PI3K pathways and RTK (Supplementary Table 9 , Fig. 4b ). The MAPK signalling pathway was enriched 1.34 fold (Fisher's exact test, q < 1 X 10 -51 ) and bore mutations in 179 of 183 (98 %) samples.
Samples that harboured a mutated gene in both the MAPK and PI3K pathways had the highest proportion of p-ERK positive tumour nuclei, whereas samples that were wild-type for all genes in the PI3K and MAPK pathways had the lowest proportion ( Fig. 4c, 4d ). The highest p-AKT activation levels were seen in cases with only PI3K altered, whereas MAPK only and MAPK/PI3K wild-type cases had the lowest (differences not significant, one-way ANOVA and post hoc Tukey's test).
Nearly all cutaneous (138/140, 99 %) and most non-cutaneous (39/43, 91 %) melanomas harbored a SNV/indel or SV breakpoint in one or more genes that can confer sensitivity to an agent that is FDA-approved or currently in a cancer clinical trial (Extended data 10). The frequency of mutation and CNV of some potentially actionable genes (CCND1, CCND2, KIT, KRAS, MDM2 and PIP5K1A) was significantly higher in non-cutaneous compared with cutaneous melanomas (two-proportion z-test, all P < 0.05).
Discussion
This is the largest WGS analysis of melanoma to date and the largest to compare cutaneous, acral and mucosal subtypes. Acral and mucosal melanomas showed a dramatically different genomic landscape from cutaneous melanoma, with a far lower mutation burden dominated by large-scale structural variants. Novel mutagen signatures in cutaneous melanomas likely reflect uncharacterised mechanisms of UVR damage. The principal mutation mechanisms driving mucosal and most acral melanomas were, in contrast, not attributable to UVR and imply novel carcinogenic exposures that are shared with cancers other than skin cancer. Notably, some mucosal melanomas exhibited SMG (GNAQ, SF3B1) previously characteristic of uveal melanoma. In further contrast to cutaneous melanomas, acral and mucosal melanomas were infrequently driven by TP53, PTEN or RB1 pathway lesions, and exhibited a variety of "triple wild-type" mechanisms such as KIT mutations and focal amplifications of KIT, CCND1, MDM2 and KRAS. Novel recurrently fused genes were also identified (PAK1, DGKB). Most cutaneous and noncutaneous melanomas exhibited mutations in genes for which targeted therapies exist or are being evaluated in clinical trials.
Non-coding mutations were surveyed for the first time at scale in melanoma, and their significance assessed taking into account the high mutation load at TFBS in melanoma 24 .
The number of genes affected by recurrent non-coding mutations predicted to have a strong functional impact was equivalent to the number of genes affected by recurrent significant coding mutations. Eight genes in addition to TERT showed potential driver promoter mutations (BLCAP, KBTBD8, NSUN6, RALY, RNF185, RPL29, RPS27 and ZNF778).
Recurrent, likely functional 5'-UTR mutations were observed in CHCHD2, PES1 and RPS14, as well as in genes previously reported as mutated (RPS27, MRPS31). Recurrent 3'-UTR mutations were common, and of uncertain significance, although PTPRT also carries frequent coding mutations 27 .
Finally, we show the highly prevalent TERT promoter mutations in melanoma must confer selective advantage via dysregulation of telomere protection, whether via telomerase or the ALT mechanism, since they result in reduced, not increased telomere length.
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Methods
Human melanoma samples
The fresh-frozen tissue and blood samples analysed in the current study were obtained from 
DNA extractions
Tumour DNA was extracted using DNeasy Blood and Tissue Kits (69506, Qiagen Ltd), according to the manufacturer's instructions. Blood DNA was extracted from whole blood using Flexigene DNA Kits (51206, Qiagen Ltd). All samples were quantified using the NanoDrop (ND1000, Thermoscientific) and Qubit® dsDNA HS Assay (Q32851, Lifetechnologies) and DNA size and quality were tested using gel electrophoresis. Samples with a concentration of less than 50 ng/µl, or absence of a high molecular weight band in electrophoresis gels, were excluded from further analyses.
Whole genome sequencing (WGS)
WGS 
Whole genome sequence processing and quality control
Sequence data was aligned to the GRCh37 assembly using multi-threaded BWA 0. 
Somatic mutation analysis
Somatic mutations and germline variants were detected using a dual calling strategy using qSNP 40 and GATK 41 and indels of 1-50 bp in length were called with Pindel 42 and GATK. All mutations were submitted to the International Cancer Genome Consortium (ICGC) 43 Data
Coordination Centre (DCC). Mutations were annotated with gene consequence using Ensembl gene annotation with SnpEff. Somatic genes which were significantly mutated were identified using two approaches: MutSigCV and OncodriveFML 1.1 22 using a threshold of q<0.1. Significant non-coding elements were detected using OncodriveFML 1.1 22 .
Somatic copy number and ploidy were determined using the TITAN tool 44 . SV were identified using the qSV tool and chromosomes containing highly significant non-random distributions of breakpoints were identified as previously described 45 . Chromosomes identified to have clustering of breakpoints were inspected against criteria for chromothripsis 46 and the breakage-fusion-bridge cumulative rearrangement model 47 . Chromosomes with high numbers of translocations were identified with a minimum threshold of 10 translocation breakpoints per chromosome following manual review.
Mutational signatures were predicted in each sample using a published framework 1 .
Essentially the substitution mutations across the whole genome in all cases were analysed in context of the flanking nucleotides (96 possible trinucleotide combinations). Identified signatures were compared to other validated signatures and the frequency of each signature per Mb was determined.
Recurrent non-coding mutations
Statistical significance of recurrent non-coding mutations was estimated using a permutation test. A null distribution of recurrence was estimated by randomly shuffling all mutations within each sample and record number of recurrent mutations within the regions of interest.
To take into account not only the varying mutation burden but also the different mutation signatures, we restricted the random shuffling such that the mutation in the middle of a trinucleotide, ABC, was only shuffled to the same trinucleotide.
Functional impact bias of mutations in promoters, 3' UTRs and 5' UTRS
Promoters and UTRs that are likely to play a role in tumorigenesis were identified with OncodriveFML 22 : a framework able to detect signals of positive selection in both the coding and the non-coding regions of the genome by measuring the bias toward the accumulation of functional mutations. The functional impact of mutations in gene promoters was assessed using the CADD (Combined Annotation Dependent Depletion) 48 , TFBS creation, and TFBS disruption scores. The CADD scores measure the deleteriousness of mutations, and are calculated by integrating multiple annotations into a single metric by contrasting variants that survived natural selection with simulated mutations. The scores for TFBS creation (motif gain) and disruption (motif break) were computed by following the steps described by Fu et al. 49 . The score value indicates the difference between position weight matrix matching scores of the germline and mutant alleles. 5' UTRs were analyzed using the TFBS disruption scores while 3' UTRs were analyzed using the CADD scores. The statistical significance of promoters and UTRs was derived by comparing the average functional impact score of the mutations in the element with the functional impact scores obtained by permuting 100,000fold the observed mutations, maintaining their trinucleotide context. In addition, since the rate of somatic mutations in melanoma is highly increased at active transcription factor binding sites (TFBS) 24 , OncodriveFML was adapted (version 1.1) to perform a strictly local permutation in windows of 51 bp (25 nucleotides at each side of the mutation). This variation in the background model of OncodriveFML allowed us to better estimate whether the mutations observed in tumours disrupted or created TFBS more than expected by chance.
The statistical significance of promoters and UTRs mutated in at least two samples was adjusted with the Benjamini-Hochberg correction for multiple testing.
We also used miRanda v3.3a to predict whether the recurrent 3'UTR mutations alter (disrupt or create) miRNA binding sites. The 50 base sequence surrounding each 3'UTR was used as input to miRanda. miRNAs that were predicted to hit either the wild-type or mutant sequence (but not both) were considered potential targets and further filtered as follows. We required a hit to perfectly align against the seed region of the miRNA (nt 2-8), that the mutation lay within the seed, and that the predicted binding energy was higher (lower dG) in the non-hit than in the hit.
Telomere length estimation
To estimate telomere length we counted telomere motifs in the whole gene data using the qPCR-validated qmotif tool (https://sourceforge.net/p/adamajava/wiki/qMotif) implemented in JAVA using the Picard library (version 1.110). qmotif is driven by a single plain-text configuration file in the "Windows INI-file" style and the input is a WGS BAM file that has been duplicate-marked and coordinate-sorted. Essentially, qmotif uses a two-stage matching system where the first stage is a quick-but-strict string match and the second stage is a slower but more flexible regular expression match; only reads that pass stage 1 go on to the much slower match in stage 2. For telomere quantification, a string that represents 3 concurrent repeats of the canonical telomere motif (TTAGGGTTAGGGTTAGGG) was used as the stage 1 match and a simple pattern match for stage 2 which captures any read with 2 or more concurrent occurrences of the telomeric repeat with variation allowed in the first 3 bases. The relative tumour telomere length was then estimated by comparing the tumour read counts to the matched normal sample. Telomere length was validated by qPCR 50 . 
Sanger sequencing of TERT promoter
Ultra-deep custom amplicon sequencing of non-coding mutations
The 
RNA extraction and sequencing
Total RNA was extracted from fresh frozen tissue using the mirVana™ miRNA Isolation Kit (Applied Biosystems, Cat# AM1560). RNA quality and presence of a small RNA fraction were measured using the Agilent 2100 RNA 6000 Nano and small RNA kits. RNAsequencing was performed using 1 μg of total RNA, which was converted into mRNA produced and colours were overlaid using Illustrator CS6 (Adobe) onto an adapted SVG human body diagram that was created using Illustrator CS6 (Adobe). We thank Doug
Stetner for computing assistance.
Clinically actionable genes
The frequency of clinically actionable mutations was assessed by annotating genomic variants using the IntOGen Cancer Drivers Actionability (ICDA) database (2014), which identifies mutations that may confer sensitivity to therapeutic agents 53 . The ICDA database was used to assign an activating or loss of function role to mutated genes" . Loss of heterozygosity, silent mutations, deletions to activating genes or amplifications to loss of function genes were not included in the analysis. Additionally, visual inspection using the Integrative Genome Viewer (IGV, Broad) was used to identify only high confidence structural rearrangement breakpoints with clustered supporting reads with both discordant read pair and soft clipping evidence. SVs with a high incidence of random non-clustered background signal surrounding the breakpoints along with low numbers of supporting non-duplicate reads were excluded from analysis for this figure (Extended Data 10) . The proportion of tumours with a mutation to a particular actionable gene was calculated and classified based on mutation type into: 1) SNV/indel, 2) SNV/indel and SV, 3) SV or 4) copy number variation only.
Commonly mutated genes and pathways
A hand-curated list of commonly mutated tumour suppressor genes and oncogenes was created and analysed for the frequency of mutation (Fig. 4a ). Mutations were defined as SNV/indel, SV, copy number amplifications and copy number deletions. Loss of heterozygosity, silent mutations, RNA mutations, deletions to oncogenes or amplifications to tumour suppressor genes were not included in the figure. SV breakpoints were subjected to manual inspection using the Integrative Genome Viewer (IGV, Broad) and only events confirmed as somatic and predicted to alter transcription processing were considered further.
We then overlaid the alterations from Fig. 4a onto pathways defined by KEGG and GO gene sets from MSigDB v5.0. A pathway was considered altered in a given sample if at least one gene in the pathway contained an SNV/indel or SV. The pathways were then stratified according to cutaneous or non-cutaneous subtypes. A mutation file with samples IDs and their mutated pathways was entered for analysis into the OncoPrinter tool (http://cbioportal.org).
Multiplex immunofluorescent staining
MAPK and PI3K pathway status was also assessed by multiplex immunofluorescent staining for phosphorylated ERK and AKT (106/183). All immunohistochemical staining was performed on a Dako Autostainer Plus (Dako, Glostrup, Denmark) using the Dako Envision 
Data deposition
All somatic variants for this study have been submitted to the ICGC Data Coordination Centre (DCC) and are publicly available through the ICGC DCC Data Portal (https://dcc.icgc.org). The BAM files are in the EGA (accession EGAS00001001552).
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